ALACHUA, Fla.--(BUSINESS WIRE)--Dec. 19, 2005--Oragenics, Inc. (AMEX:ONI) announced today that it has completed its anticipated equity based financing with a group of accredited investors. The $1,175,000 financing provides for the issuance of 2,937,500 shares of common stock at a price of $0.40 per share and the issuance of an equal number of warrants to purchase shares of common stock that will be exercisable at $0.60 per share. As stated by Oragenics’ CFO, Paul Hassie, “This financing will help us maintain our progress with the clinical program for our SMaRT replacement therapy technology and the preclinical work for our MU 1140 antibiotic technology.”
